FDA advisory panel backing for Merck/ALK ragweed allergy immunotherapy Ragwitek

28 January 2014

The US Food and Drug Administration’s Allergenic Products Advisory Committee has voted that the available data support the efficacy and safety of US pharma giant Merck & Co’s (NYSE: MRK) Ragwitek.

Ragwitek is the proposed US trade name of the ragweed sublingual allergy immunotherapy tablet licensed to Merck for North America by Denmark-based allergy specialist ALK Abello (ALKB: DC).

The FDA is currently reviewing Merck’s Biologic License Application for Ragwitek for the treatment of ragweed pollen induced allergic rhinitis, with or without conjunctivitis, in adults 18 to 65 years of age.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK